Teladoc (NYSE:TDOC)‘s stock had its “buy” rating reissued by analysts at KeyCorp in a research note issued on Wednesday. They currently have a $41.00 price target on the health services provider’s stock. KeyCorp’s price target would indicate a potential upside of 18.84% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Robert W. Baird cut shares of Teladoc from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $14.00 to $36.00 in a research report on Monday, September 18th. Zacks Investment Research raised shares of Teladoc from a “sell” rating to a “hold” rating in a research report on Thursday, September 21st. Cantor Fitzgerald reissued a “hold” rating and issued a $31.00 price target on shares of Teladoc in a research report on Tuesday, September 26th. Piper Jaffray Companies reissued a “buy” rating and issued a $42.00 price target on shares of Teladoc in a research report on Friday, September 29th. Finally, Cowen reissued an “outperform” rating and issued a $39.00 price target on shares of Teladoc in a research report on Saturday, September 30th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $39.31.

Teladoc (NYSE:TDOC) opened at $34.50 on Wednesday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08. The company has a market cap of $2,090.00 and a price-to-earnings ratio of -23.79. Teladoc has a 12 month low of $15.65 and a 12 month high of $38.40.

Teladoc (NYSE:TDOC) last issued its earnings results on Wednesday, November 1st. The health services provider reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). The firm had revenue of $68.70 million for the quarter, compared to analyst estimates of $67.53 million. Teladoc had a negative return on equity of 29.70% and a negative net margin of 45.64%. The business’s revenue for the quarter was up 112.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.33) EPS. analysts expect that Teladoc will post -1.56 EPS for the current year.

In other news, VP Mark Hirschhorn sold 35,000 shares of the company’s stock in a transaction dated Tuesday, October 17th. The shares were sold at an average price of $32.84, for a total value of $1,149,400.00. Following the completion of the sale, the vice president now directly owns 20,887 shares of the company’s stock, valued at $685,929.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Jason N. Gorevic sold 100,000 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the completion of the sale, the chief executive officer now directly owns 718,261 shares of the company’s stock, valued at $23,695,430.39. The disclosure for this sale can be found here. Insiders sold 210,000 shares of company stock valued at $6,889,350 over the last ninety days. Corporate insiders own 4.47% of the company’s stock.

Several large investors have recently made changes to their positions in the company. FMR LLC raised its holdings in shares of Teladoc by 1.3% in the second quarter. FMR LLC now owns 8,209,737 shares of the health services provider’s stock valued at $284,879,000 after buying an additional 106,500 shares during the last quarter. BlackRock Inc. raised its holdings in Teladoc by 42.9% during the second quarter. BlackRock Inc. now owns 3,844,402 shares of the health services provider’s stock worth $133,400,000 after purchasing an additional 1,154,852 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Teladoc by 24.4% during the third quarter. JPMorgan Chase & Co. now owns 3,313,729 shares of the health services provider’s stock worth $108,193,000 after purchasing an additional 650,129 shares in the last quarter. Vanguard Group Inc. raised its holdings in Teladoc by 11.5% during the second quarter. Vanguard Group Inc. now owns 3,041,725 shares of the health services provider’s stock worth $105,547,000 after purchasing an additional 314,646 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its holdings in Teladoc by 2.2% during the third quarter. Eagle Asset Management Inc. now owns 2,106,830 shares of the health services provider’s stock worth $72,053,000 after purchasing an additional 45,794 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Teladoc (TDOC) Earns “Buy” Rating from KeyCorp” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2018/01/10/teladoc-tdoc-earns-buy-rating-from-keycorp.html.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.